AbbVie initiates phase 3 multiple myeloma trial
Betsy Goodfellow | June 6, 2024 | News story | Medical Communications | ABBV-383, AbbVie, Oncology, clinical trial, multiple myeloma
AbbVie has announced that it has dosed the first patient in its phase 3 CERVINO trial, which aims to assess ABBV-383 for the treatment of patients with relapsed/refractory multiple myeloma (r/r MM).
ABBV-383 is a ‘distinctive B-cell maturation antigen (BCMA) and CD3 bispecific antibody T-cell engager composed of bivalent BCMA-binding domains allowing for high BCMA-avidity and a low-affinity CD3 binding domain’, according to press release.
The trial is a multicentre, randomised, open-label study, which will compare ABBV-383 with standard available therapies in a selection of patients with r/r MM who have already received at least two lines of prior therapy.
Mariana Cota Stirner MD, vice president, therapeutic area head oncology and haematology at AbbVie, commented: “The start of the CERVINO phase 3 trial marks an important step forward in AbbVie’s continued commitment to advance new oncology treatments and elevate the standard of care for blood cancer patients. ABBV-383 is being evaluated with monthly dosing from the beginning of treatment, with the goal of maximising treatment simplicity for physicians and patients, if proven in the clinical trials.”
Dr Peter Voorhees, clinical professor of medicine and director of plasma cell disorders at Atrium Health Levine Cancer Institute, added: “Despite notable advances in treatment, most patients with MM will eventually relapse. Patients with advanced disease, especially in the community setting, often have limited access to novel treatment options and existing options have a high treatment burden, including frequent dosing. The CERVINO phase 3 trial is designed to evaluate the efficacy of ABBV-383 with monthly dosing and we look forward to seeing the data as it emerges.”
Betsy Goodfellow
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
